5 minutes agoEU backs Israeli anti-cronobrus drug
Periskopi(6 years ago)
(6 years ago)The European Union has decided to back 50m euros, a counter-taker COVIED-19 under way by the Israeli Plullistm firm. From tests conducted in Israel and the United States, the treatment has resulted in 100% success, a level that has so far not been achieved by any drug being tested against the coronary. Signature [...]
The European Union has decided to back 50m euros, a counter-taker COVIED-19 under way by the Israeli Plullistm firm.
From tests conducted in Israel and the United States, the treatment has resulted in 100% success, a level that has so far not been achieved by any drug being tested against the coronary.
The Haifa-based pharmaceutical firm Plutostem has developed a therapy that uses placenta to develop reprocessable cells to treat damaged organs as a result of coronary infection. Cure releases proteins, which treat organs damaged by COVID-19, such as heart, lungs, kidneys, etc., writes TV Klan.
This cure completely healed six patients in Israel who were in danger of life because of coronary infection. This month another patient in the United States was healed, who agreed to undergo trial with this treatment.
Currently, the cure is in the third advanced phase of human evidence. Funds granted by the European Union and the European Investment Bank cover 50% of the expenditures for development of this cure.
The Israeli firm stands out for the development of many treatments, including several studies of a vaccine for protection from the atomic radiation of American soldiers conducted three years ago.
